In an initiative to increase the efficiency of drug manufacturing in the United States, the FDA has proposed a streamlined ...
Lupin Pharmaceuticals, the U.S. unit of India’s Lupin Limited, issued a voluntary recall of more than 2.5 million bottles of prednisolone acetate ophthalmic suspension after an undisclosed contaminant ...
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal cancer, the ...
Even as the effort has met with fierce pushback from drugmakers, trade groups and opposition parties in the country’s own ...
The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...
Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...
The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and ...
The pharmaceutical industry is reaching a turning point in patient support. | Life sciences leaders say patient support is ...
In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines. While AbbVie’s market ...
The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent ...
Biopharma giants Eli Lilly and Regeneron and rapidly growing contract manufacturers Fujifilm and Cellares, are among the ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. Thanks to an FDA nod on July 10, Padcev and Keytruda have become the first muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results